Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from A Diabetes Outcome Progression Trial (ADOPT)

Authors :: Kahn, Steven E.
Haffner, Steven M.
Viberti, Giancarlo
Herman, William H.
Lachin, John M.
Kravitz, Barbara G.
Yu, Dahong
Paul, Gitanjali
Holman, Rury R.
Zinman, Bernard
Source :: Diabetes Care. January 1, 2010, Vol. 33 Issue 1, p177, 7 p.
Publication Year :: 2010
Abstract: OBJECTIVE--C-reactive protein (CRP) is closely associated with obesity and cardiovascular disease in both diabetic and nondiabetic populations. In the short term, commonly prescribed antidiabetic agents have different effects on CRP; [...]

Subjects :: Obesity -- Patient outcomes -- Rites, ceremonies and celebrations
Diabetes -- Patient outcomes -- Rites, ceremonies and celebrations
Insulin resistance -- Patient outcomes -- Rites, ceremonies and celebrations
Glibenclamide -- Rites, ceremonies and celebrations
Cardiovascular diseases -- Patient outcomes -- Rites, ceremonies and celebrations
C-reactive protein -- Rites, ceremonies and celebrations
Thiazolidinediones -- Rites, ceremonies and celebrations
Health

Full Text Access

Tools